Drug repositioning: Identifying and developing new uses for existing drugs

被引：2207

作者：

Ashburn, TT ^{[1
]}

Thor, KB ^{[1
]}

机构：

[1] Dynogen Pharmaceut Inc, Boston, MA 02116 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2004年 / 3卷 / 08期

关键词：

D O I：

10.1038/nrd1468

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Biopharmaceutical companies attempting to increase productivity through novel discovery technologies have fallen short of achieving the desired results. Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of production to biotechnology companies. More and more companies are scanning the existing pharmacopoeia for repositioning candidates, and the number of repositioning success stories is increasing.

引用

页码：673 / 683

页数：11

共 62 条

[31] Longman R., 2004, IN VIVO, V22, P17
[32] LONGMAN R, 2004, IN VIVO 0217
[33] *MERCK CO, 2004, OTH FIN DISCL
[34] Duloxetine versus placebo in the treatment of stress urinary incontinence
Norton, PA
Zinner, NR
Yalcin, I
Bump, RC
[J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (01) : 40 - 48
[35] OSTROV BF, 2004, SAN JOSE MERCURY NEW, pE1
[36] *PARK INF EXCH NET, 2004, PARK LIST DRUG DAT C
[37] PEGG AE, 1988, CANCER RES, V48, P759
[38] *PFIZ, 2004, PFIZ 8K FIL
[39] *PFIZ, 2004, PFIZ 8 FIL
[40] *PHARM UPJ INC, RES INF

← 1 2 3 4 5 6 7 →